Debt-Laden Valeant Unloads iNova Pharma In $930 Million Deal Post author:Sam Post published:June 7, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Pharming Group Report On Preliminary Financial Results For 2016 March 8, 2017 Catabasis To Present Results From The Open-Label Extension Of The Movedmd Phase II Trial Of Edasalonexent In Duchenne Muscular Dystrophy In A Late Breaking Session Of The World Muscle Society September 14, 2017 Misonix Reports Receipt of Deficiency Letter From The February 13, 2017
Catabasis To Present Results From The Open-Label Extension Of The Movedmd Phase II Trial Of Edasalonexent In Duchenne Muscular Dystrophy In A Late Breaking Session Of The World Muscle Society September 14, 2017